IRMD
IRadimed Corporation
NASDAQ · Healthcare · Medical - Devices · US
$83.45
−3.63%Year over year
Reported trailing growth
- Revenue
- +11.2%
- EBITDA
- +17.0%
- EBIT
- +15.7%
- EPS
- +11.7%
- Free cash flow
- +84.0%
- Operating cash flow
- -0.0%
Forward estimates
Based on analyst estimates
- Revenue
- +15.4%
- EBITDA
- +26.1%
- EPS
- +29.7%
Three-year CAGR
- Revenue
- +16.3%
- EBITDA
- +22.2%
- EBIT
- +18.7%
- Net income
- +20.6%
- EPS
- +20.2%
- Free cash flow
- +28.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026